Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2

被引:25
|
作者
Itoh, T
Itagaki, S
Sumi, Y
Hirano, T
Takemoto, I
Iseki, K
机构
[1] Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Clin Pharmaceut & Therapeut, Kita Ku, Sapporo, Hokkaido 0600812, Japan
[2] Sapporo Social Insurance Gen Hosp, Dept Pharm, Atsubetsu Ku, Sapporo, Hokkaido 0048618, Japan
关键词
irinotecan; diarrhea; Caco-2; cells; baicalin;
D O I
10.1007/s00280-004-0937-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim of this study was to investigate the transport mechanisms of transporters that contribute to the intestinal uptake of 7-ethyl-10-hydroxycamptothecin (SN-38). Methods: Human intestinal epithelial Caco-2 cells were used to investigate the mechanistic basis of transepithelial uptake of SN-38. We investigated the characteristics of SN-38 uptake into Caco-2 cells. The effects of baicalin and sulfobromophthalein (BSP) on the uptake of SN-38 by Caco-2 cells were examined. Results: Uptake of SN-38 was significantly reduced at 4 degrees C. Baicalin inhibited the uptake of SN-38 in a concentration-dependent manner. BSP significantly reduced the uptake of SN-38. However, probenecid, pravastatin and grepafloxacin did not affect the uptake of SN-38. Conclusions: The results suggest that a specific transport system mediates the uptake of SN-38 across the apical membrane in Caco-2 cells.
引用
收藏
页码:420 / 424
页数:5
相关论文
共 50 条
  • [31] Uptake and intracellular fate of L-DOPA in a human intestinal epithelial cell line: Caco-2
    Vieira-Coelho, MA
    Soares-Da-Silva, P
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 1998, 275 (01): : C104 - C112
  • [32] Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
    E. Gupta
    Xiaolin Wang
    Jacqueline Ramirez
    M. J. Ratain
    Cancer Chemotherapy and Pharmacology, 1997, 39 : 440 - 444
  • [33] Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
    Gupta, E
    Wang, XL
    Ramirez, J
    Ratain, MJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 39 (05) : 440 - 444
  • [34] Fasting reduces the systemic exposure to irinotecan and its active metabolite SN-38
    Huisman, Sander A.
    de Bruijn, P.
    Moghaddam-Helmantel, I. M. Ghobadi
    IJzermans, J. N. M.
    Wiemer, E.
    Mathijssen, A. H. J.
    de Bruin, R. W. F.
    CANCER RESEARCH, 2014, 74 (19)
  • [35] In vitro activation of irinotecan to SN-38 by human liver and intestine
    Ahmed, F
    Vyas, V
    Cornfield, A
    Goodin, S
    Ravikumar, TS
    Rubin, EH
    Gupta, E
    ANTICANCER RESEARCH, 1999, 19 (3A) : 2067 - 2071
  • [36] Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38
    Charasson, V
    Bellott, R
    Meynard, D
    Longy, M
    Gorry, P
    Robert, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (06) : 528 - 535
  • [37] In Vitro Binding and Partitioning of Irinotecan (CPT-11) and its Metabolite, SN-38, in Human Blood
    Olivier Combes
    Jérôme Barré
    Jean-Claude Duché
    Laurent Vernillet
    Yves Archimbaud
    Michael P. Marietta
    Jean-Paul Tillement
    Saïk Urien
    Investigational New Drugs, 2000, 18 : 1 - 5
  • [38] In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood
    Combes, O
    Barré, J
    Duché, JC
    Vernillet, L
    Archimbaud, Y
    Marietta, MP
    Tillement, JP
    Urien, S
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (01) : 1 - 5
  • [39] Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines
    Haatisha Jandu
    Kristina Aluzaite
    Louise Fogh
    Sebastian Wingaard Thrane
    Julie B. Noer
    Joanna Proszek
    Khoa Nguyen Do
    Stine Ninel Hansen
    Britt Damsgaard
    Signe Lykke Nielsen
    Magnus Stougaard
    Birgitta R. Knudsen
    José Moreira
    Petra Hamerlik
    Madhavsai Gajjar
    Marcel Smid
    John Martens
    John Foekens
    Yves Pommier
    Nils Brünner
    Anne-Sofie Schrohl
    Jan Stenvang
    BMC Cancer, 16
  • [40] In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines
    Kano, Y
    Akutsu, M
    Tsunoda, S
    Mori, K
    Suzuki, K
    Adachi, KI
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (02) : 91 - 98